摘要
目的探讨吉西他滨+顺铂+地塞米松(GDP)方案化疗治疗弥漫大B细胞淋巴瘤的效果及其对预后的影响。方法选择成都军区总医院2012年1月—2014年12月收治的68例弥漫大B细胞淋巴瘤,根据治疗方法分为对照组30例和观察组38例。对照组在常规治疗基础上予以地塞米松+依托泊苷+异环磷酰胺+顺铂(DICE)方案化疗,观察组予以GDP方案化疗,治疗结束后比较2组近期疗效和远期预后效果,并分析影响患者预后的相关因素。结果观察组总有效率高于对照组(P<0.05)。观察组血栓形成率高于对照组,脱发、外周神经炎和胃炎发生率低于对照组(P<0.05)。2年随访结束后,观察组无事件和无进展生存率均高于对照组(P<0.05)。Ann Arbor分期、年龄、骨髓浸润、国际预后指数评分和化疗方案均为影响预后的独立危险因素(P<0.05)。结论 GDP化疗方案可明显提高弥漫大B细胞淋巴瘤患者近期疗效,延长远期生存时间,且安全性较高。
Objective To investigate effect of Gemcitabine+Dexamethasone+Cisplatin(GDP)chemotherapy plan in treatment of diffuse large B-cell lymphoma and its effect on prognosis.Methods A total of 68 patients with diffuse large B-cell lymphoma admitted during January 2012 and December 2014 were divided into control group(n=30)and observation group(n=38)according to therapeutic methods.Control group was treated with DICE chemotherapy plan on the basis of routine treatment,while observation group was treated with GDP chemotherapy plan on the basis of routine treatment.After treatment,short-term curative effect and long-term prognosis were compared,and related factors affecting prognosis were analyzed in two groups.Results The total effective rate was significantly higher in observation group than that in control group(P<0.05).In observation group,thrombosis rate was significantly higher,while incidence rates of baldness,neuropathy and gastritis were significantly lower than those in control group(P<0.05).At the end of 2 years of follow-up,no event and progression-free survival rates in observation group were significantly higher than those in control group(P<0.05).Ann Arbor stage,age,marrow infiltration,international prognosis index(IPI)score and chemotherapy plan were related factors affecting prognosis(P<0.05).Conclusion GDP chemotherapy plan may significantly improve short-term curative effect and prolong long-term survival time with good safety in treatment of patients with diffuse large B-cell lymphoma.
作者
李业成
何光翠
刘芳
吕素娟
成晓敏
张珊
邓锐
苏毅
LI Yecheng;HE Guangcui;LIU Fang;LYU Sujuan;CHENG Xiaomin;ZHANG Shan;DENG Rui;SU Yi(Department of Hematology,General Hospital of Chengdu Military Area Command,Chengdu 610083,China)
出处
《解放军医药杂志》
CAS
2018年第1期23-26,共4页
Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金
四川省科技计划项目(2014JY0149)
关键词
淋巴瘤
大B细胞
弥漫性
抗肿瘤联合化疗方案
治疗结果
预后
Lymphoma,large B-cell,diffuse
Antineoplastic combined with chemotherapy protocols
Treatment outcome
Prognosis
